Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Endologix Demonstrates New IntuiTrak Endovascular AAA System At XXII Endovascular Interventions conference

Endologix, Inc announced that a live-case demonstration of its new IntuiTrak Delivery System was featured at the International Congress XXII Endovascular Interventions conference in Scottsdale, Ariz. The procedure was performed by Zvonimir Krajcer, MD; Edward Diethrich, M.D., and Venkatesh G. Ramaiah, M.D. The endovascular AAA procedure was successfully performed with local anesthesia and a percutaneous approach. IntuiTrak is an innovative system developed for the minimally invasive delivery and deployment of the Powerlink stent graft. The device is presently in limited market release following US Food and Drug Administration approval in October 2008. IntuiTrak's deployment mechanism and design simplifies standard vascular delivery of the Powerlink device and provides accuracy and control. The low-profile delivery system features advanced hemostasis control, enhanced flexibility and a hydrophilic coating to facilitate smooth delivery, especially in patients with limited or difficult vascular access. "Due to its low-profile and integrated sheath, IntuiTrak is ideal for the percutaneous treatment of patients with AAA," said Dr. Krajcer. "I have used the new device in eight cases so far, and have experienced 100% technical success and exceptional patient outcomes." "The International Congress provides an excellent opportunity to showcase IntuiTrak before a prestigious audience of physician thought-leaders in the treatment of AAA," said John McDermott, Endologix President and CEO. "With the procedural advantages of IntuiTrak, combined with the exceptional long-term clinical results of the Powerlink device, we believe we are providing physicians with a compelling technology to treat their AAA patients. We are very encouraged by the physician feedback received to-date and are on schedule for a full-market launch in the US in the second quarter of 2009."